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TRANSMYOCARDIAL REVASCULARIZATION FOR CARDIAC TRANSPLANTATION ALLOGRAFT
VASCULOPATHY
P. Michael McFadden, MD, Robert J. Robbins, MD, John L. Ochsner, MD, Clifford H. Van Meter, MD, and
Susan Majorie, RN, New Orleans, La.
Cardiac allograft vasculopathy is a leading cause of
death after heart transplantation.1 Virtually all cardiac
transplant recipients exhibit some histopathologic evi-
dence of vasculopathy 1 year after transplantation.2 Man-
agement options for patients with myocardial ischemia
caused by this condition have been limited to medical
therapy, coronary revascularization, or cardiac retrans-
plantation. To determine whether transmyocardial laser
revascularization (TMR) is an effective treatment for
cardiac allograft vasculopathy after cardiac transplanta-
tion, we performed holmium laser revascularization on
four patients with myocardial ischemia who met research
protocol criteria.
Clinical summaries
PATIENT 1. A 60-year-old man had angina and exertional
dyspnea 35 months after heart transplantation for isch-
emic cardiomyopathy. Coronary angiography demon-
strated allograft vasculopathy. Percutaneous transluminal
coronary angioplasty of the left anterior descending sys-
tem and stenting of the right coronary artery provided
transient relief of symptoms. Recurrent angina 1 year
later prompted cardiac catheterization, which revealed
diffuse vasculopathy. A dipyridamole thallium perfusion
study revealed reversible global ischemia. TMR and tri-
ple-vessel coronary artery bypass were performed 62
months after transplantation (Table I). Recovery was
uneventful and the patient remained free of symptoms.
The marked improvement noted on the initial 3-month
postoperative dipyridamole thallium perfusion study was
sustained on repeated studies 6 and 18 months after the
operation. Improvement in perfusion was apparent in
both bypassed and lased areas of myocardium.
PATIENT 2. A 54-year-old woman began having angina
22 months after transplantation for ischemic cardiomyop-
athy. Her symptoms were initially relieved with nitrates,
but recurrent angina prompted angiography, which re-
vealed nonbypassable allograft vasculopathy. A dipyrid-
amole thallium perfusion study demonstrated significant
reversible ischemia. TMR was performed to areas of
ischemic myocardium (Table I). After the operation the
patient was angina free. She had marked and sustained
improvement in perfusion to the anterior and anterolat-
eral walls on dipyridamole thallium studies 3 and 6
months after the procedure (Fig. 1). The patient remained
free of symptoms and active until her death from a
myocardial infarction 10 months after TMR.
PATIENT 3. A 52-year-old man began having angina 24
months after heart transplantation for ischemic cardiomy-
opathy. Coronary angiography performed 1 year later
demonstrated proximal atherosclerotic stenoses and dif-
fuse allograft vasculopathy. Percutaneous transluminal
coronary angioplasty of a proximal stenosis of the left
anterior descending coronary artery provided temporary
relief, but class IV angina symptoms recurred within 1
year. A second angiogram revealed diffuse allograft vas-
culopathy and significant proximal triple-vessel disease.
Dobutamine-stress echocardiography induced severe an-
gina and produced little alteration in impaired allograft
function. TMR was performed to the area of myocardium
supplied by the nonbypassable left anterior descending
and diagonal coronary arteries, and concomitant coronary
bypass was performed to the circumflex and right coronary
systems 61 months after transplantation (Table I). Recov-
ery was uneventful and the patient was angina free.
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Fig. 1. Stress dipyridamole thallium perfusion study (left) demonstrating markedly decreased perfusion of
the anterior and lateral walls in a patient with cardiac allograft vasculopathy. Postoperative study 3 months
after TMR (right) demonstrates essentially normal myocardial perfusion.
Table I. Initial series of cardiac transplant recipients with allograft vasculopathy treated with TMR
Patient
CHF* Angina† Perfusion study
TMR
(location and no.)
CABG
(no. and site)Pre Post Pre Post Pre 3 or 4 months 6 months
1 0 0 III 0 Large reperfusion
defect in ant-sept,
apex, and inf-lat
regions
Small reperfusion
defect in ant-sept
and inf-lat regions
Same as at 3 months.
New reperfusion
defect in ant-lat
region
Anterior 2
Ant-lat 5
Post-lat 6
Apex 2
Inferior 2
LITA-LAD
SVG-PDA
SVG-OM
2 I I IV 0 Large reperfusion
defect in ant, ant-
lat, and inf regions
Decreased reperfu-
sion defect in ant,
ant-lat, and inf
regions
Similar to 3 months Anterior 13
Ant-lat 6
Post-lat 5
Apex 7
NA
3 0 0 IV I Stress-induced angina
(10:10), normal LV
function with stress
No angina, normal
LV function with
stress
NA Anterior 9
Ant-lat 5
Apex 4
SVG-OM
SVG-RCA
4 III III IV 0-I Improved LV func-
tion with stress,
1 viability inf, ant,
and septal regions
Improved LV func-
tion with stress,
decrease in hypo-
kinesis regions of
LV
NA Anterior 10
Ant-lat 7
Post-lat 3
Apex 7
NA
CHF, Congestive heart failure; CABG, coronary artery bypass graft; LITA, left internal thoracic artery; LAD, left anterior descending; SVG, saphenous vein
graft; PDA, posterior descending artery; OM, obtuse marginal coronary artery; NA, not applicable; LV, left ventricular (ventricle); RCA, right coronary artery;
ant, anterior; lat, lateral; inf, inferior; post, posterior; sept, septal.
*New York Heart Association Heart Failure classification.
†Canadian Cardiovascular Society anginal score.
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Dobutamine-stress echocardiography induced no angina,
and left ventricular function was normal with stress 4
months after the operation. Fourteen months after TMR
the patient reported mild class II angina symptoms.
PATIENT 4. A 64-year-old man with ischemic cardio-
myopathy began having symptoms of heart failure 49
months after heart transplantation. He was treated
medically for 2 years before severe class IV angina and
persistent heart failure prompted evaluation. Coronary
angiography revealed diffuse allograft vasculopathy that
was not amenable to coronary revascularization. Dobu-
tamine-stress echocardiography documented enhanced
allograft left ventricular function with stress and indi-
cated anterior, inferior, and septal wall viability. The
patient underwent TMR of the ischemic myocardium 50
months after transplantation (Table I). After the oper-
ation the patient had relief of angina but continued to
experience symptoms of class III heart failure. Dobu-
tamine-stress echocardiography performed 4 months
after the operation demonstrated an overall improve-
ment in allograft function with stress, particularly in
areas that were more severely hypokinetic. His status
was stable 14 months after TMR.
Discussion. TMR has yielded favorable early and inter-
mediate-term relief of angina in patients with otherwise
inoperable coronary artery disease.3-6 In addition, im-
provement in left ventricular ejection fraction, wall mo-
tion, and relative subendocardial perfusion have been
recently demonstrated.5 Whether the response to TMR is
due to creation of intramyocardial channels, initiation of
angiogenesis and neovascularization, or alteration in pain
perception resulting from a denervation phenomenon has
not been established. Despite uncertainties regarding the
exact mechanism by which TMR is effective, favorable
results observed in these patients prompted us to use laser
revascularization in cardiac transplant recipients with
myocardial ischemia caused by severe allograft vasculopa-
thy.
Two distinct lesions have been described angiographi-
cally in cardiac allograft vasculopathy.1, 2 Atheromatous
lesions of the proximal and middle thirds of the coronary
arteries, similar in distribution to native coronary artery
disease, have been termed type A lesions. In contrast, type
B lesions are described as long, obliterative, tubular
lesions within the distal third of the coronary arteries.
Type B lesions result from intimal fibroproliferation and
represent the most common vascular lesion encountered
after heart transplantation. Immunologic and traditional
risk factors are likely co-contributors to cardiac allograft
vasculopathy.7, 8
Treatment options available for patients with type A
lesions are medical therapy, coronary bypass, angioplasty,
coronary stenting, or cardiac retransplantation. Most pa-
tients, however, display both type A and type B coronary
lesions, and adequate treatment may best be achieved
with a combined procedure such as direct coronary revas-
cularization and TMR. This poses a problem in evaluating
the efficacy of TMR. The role for TMR will best be
delineated in patients with nonreconstructable coronary
vascular disease who are not candidates for cardiac re-
transplantation and who undergo TMR alone.
Cardiac transplant recipients are a challenging group to
follow up objectively. Patients with accelerated coronary
allograft vasculopathy are commonly symptom free and
frequently present with congestive heart failure, arrhyth-
mias, silent myocardial infarction, or sudden death. Inas-
much as posttransplantation vasculopathy is a common
cause of death after cardiac transplantation,1 routine
heart catheterization and coronary arteriography to mon-
itor these patients is recommended. Coronary arteriogra-
phy has been the best means of establishing the presence
of allograft vasculopathy. However, the utility of arteriog-
raphy is limited in the presence of type B lesions because
the extent of disease is often underestimated. Dipyridam-
ole thallium studies were useful in identifying two of our
patients with viable myocardium who would benefit from
TMR, as well as in evaluating the postoperative response.
Intracoronary ultrasonography, although not used in our
patients, may prove useful to corroborate or further
evaluate the progression of this disease. Recent evidence
indicates that dobutamine-stress echocardiography may
be superior to dipyridamole thallium studies in screening
for allograft vasculopathy, because the former is not
influenced by the blunted chronotropic response to adren-
ergic stimulation commonly observed in transplanted
hearts.9
Cardiac allograft vasculopathy remains a leading cause
of death in the heart transplant population. Very few
treatment options exist for this form of accelerated ath-
erosclerosis. Laser revascularization has demonstrated
favorable early results and may serve as a viable alterna-
tive for patients with allograft vasculopathy who are
unresponsive to medical management and who are not
candidates for coronary revascularization or cardiac re-
transplantation. The long-term results of this procedure in
cardiac allograft vasculopathy await further study and
analysis.
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